1443 Results
Sort By:
Published on May 7, 2024
Broken String Biosciences and the Francis Crick Institute are partnering to develop novel applications for the start-up’s proprietary DNA break-mapping platform, INDUCE-seq, to investigate the impact of genomic instability in the development of amyotrophic lateral sclerosis (ALS). The partnership will examine DNA break-mapping technology and advance understanding of genomic instability…
Published on June 5, 2023
After decades of research, cell and gene therapies are gaining traction in the biotech industry. Here are five investor-favored private startups with products already in clinical development. While conventional medications are often effective at controlling symptoms or modifying a disease, there are many conditions where their benefits are limited, such…
Published on October 20, 2022
Xcell Biosciences and aCGT Vector have announced a collaboration for manufacturing and analysis around personalized cell and gene therapies for cancer patients. aCGT Vector will provide its point-of-care GMP-licensed manufacturing platform to validate Xcellbio’s manufacturing and analytical AVATAR AI technology for use in precision cancer treatment. The partnership pairs aCGT’s…
Published on October 14, 2022
Sponsored content brought to you by The success of cell therapy products, including CAR-T cell therapy, is significantly dependent upon the material selection strategies set in the early stages of development. These strategies encompass raw materials (i.e., ancillary) throughout the production process. To facilitate the translation into clinical trials and…
Published on January 5, 2021
Get the eBook The promise of cell and gene therapies to solve some of our most challenging conditions, from rare diseases to cancers, has led this field to remain on the forefront of innovation. Advances in innovative technologies coupled with deeper scientific knowledge in cellular and molecular biology spurred a…
Published on July 24, 2020
Content sponsored by As more knowledge is revealed about the genetic underpinnings of cancers, cell and gene therapies (CGT) are playing an increasingly important role in treating oncology patients. The development of chimeric antigen receptor T cell (CAR-T cell) therapies—such as Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel)—and their success in…
Published on February 13, 2020
The coming decade is guaranteed to bring a panoply of emerging fields will help us better understand the intersection between genetics and health and how to incorporate them into routine medical practice. Polygenic risk scores (PRS) is, perhaps, at the top of the “must watch” list. With a firm footing…
Published on April 25, 2024
In a bold move to strategically grow its specialty pharmacy services, Walgreens will offer gene and cell therapies. The company yesterday introduced Walgreens Specialty Pharmacy, a move it says will expand access to care for patients with complex, chronic conditions, and will grow the company’s business. This includes a new…
Published on April 21, 2023
A combined cell and gene therapy based on growth factor release could help create personalized therapies for several neurodegenerative diseases, research suggests. The treatment uses induced pluripotent stem cells (iPSCs) to create neural progenitor cells that produce a protein called glial cell line-derived neurotrophic factor (GDNF). The study showed that…
Published on June 28, 2024
AbbVie this week acquired Celsius Therapeutics, whose focus is on “pioneering new precision medicines in inflammatory disease by harnessing the power of single-cell RNA sequencing and human biology at scale.” AbbVie acquired all outstanding Celsius equity for $250 million in cash. “AbbVie shares our excitement about the potential of TREM1…
Published on June 25, 2024
Promising new data from a trial of Vertex’s early phase islet cell therapy VX-880 for type 1 diabetes (T1D) trial showed three patients, with 12 months of follow-up, reached insulin independence. All of the dozen patients in the trial showed improvement over all—they received the full dose of VX-880 and…
Published on June 23, 2024
Harith Rajagopalan, MD, PhD, founded Fractyl Health with the vision of eliminating obesity, and it looks like his idea for how to do that has gained some preclinical steam. The metabolic therapeutics company has new data from Rejuva—its adeno-associated virus (AAV)-based glucagon-like peptide-1 (GLP-1) pancreatic gene therapy program designed to…
Published on June 20, 2024
A novel technique could potentially eradicate the toxic conditioning process required to effectively transplant hematopoietic stem and progenitor cells (HSPCs), which play a crucial role in treating blood disorders like sickle cell disease and β-thalassemia. Researchers from Stanford University and the University of California, San Francisco (UCSF) utilized CRISPR-Cas9 to…
Published on June 20, 2024
Researchers from the U.S. National Cancer Institute (NCI) have developed a chemotherapy-free, targeted treatment regimen that leads to durable remissions in people with certain types of diffuse large B-cell lymphoma (DLBCL). The five-drug ViPOR regimen, named for its inclusion of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, synergistically targets multiple molecular…
Published on June 18, 2024
A new study by researchers at Memorial Sloan Kettering Cancer Center (MSK) has found that in fasting mice, natural killer (NK) cells had their metabolisms “rewired.” Ultimately, the NK cells improved their ability to survive the rigors of the tumor microenvironment. Also, they fought cancer more effectively. The MSK researchers…